Column - June 20, 2022
Advice to smaller listed Swedish Life Science companies
Most listed Swedish biotech companies have cash and financing that is sufficient to last until 2023 or longer. The few who do not have this should probably hurry while there is time. During 2023-2025, many companies will return for new funds and competition will be fierce. In addition, there are also many listed diagnostics and […]
Biotech Business - June 16, 2022
Alvotech debuts on Nasdaq
Alvotech has announced that its ordinary shares and warrants will begin trading on the Nasdaq Stock Market LLC on Thursday, June 16, under the new ticker symbols “ALVO” and “ALVOW”, respectively. This follows the completion of the company’s business combination with Oaktree Acquisition Corp. II (“OACB”), a special purpose acquisition company sponsored by an affiliate […]
Agreement - June 16, 2022
BioInvent and Exelixis establish exclusive agreement
The two companies have entered into an option and license agreement focused on the identification and development of novel antibodies for use in IO therapeutics. The collaboration is intended to expand Exelixis’ portfolio of antibody-based therapies and will combine BioInvent’s cancer immunology and antibody biology expertise with Exelixis’ expertise and resources in antibody engineering and […]
Biotech Business - June 15, 2022
TILT Biotherapeutics receives over 10 million USD in financing
TILT Biotherapeutics has completed the first close of its financing round raising 10.7 million USD. The round was led by Lifeline Ventures and was joined by Tesi (Finnish Industry Investment Ltd). “We support resilient founders. We saw early on the enormous potential in TILT’s innovative approach to boost the patient’s T cell immune response to […]
Biotech Business - June 15, 2022
BioLamina opens an office in Boston
BioLamina has announced plans to open an office in the US to further fuel company growth and market expansion. The new office will be in Boston, MA. This strategic move will help BioLamina to better support existing and new customers in the US and brings the company closer geographically to world-renowned science hubs, it states. […]
Biotech Business - June 9, 2022
Immunicum received FDA Orphan Drug Designation
Immunicum has been granted an Orphan Drug Designation (ODD) for ilixadencel in the treatment of Gastrointestinal Stromal Tumors (GIST). This designation confirms the need and potential for ilixadencel as a new treatments for patients with GIST, which is a rare and difficult to treat subgroup of cancers reffered to as Soft Tissue Sarcoma (STS), states […]
